Miyata M, et al. - In this retrospective, observational study, researchers assessed the 5-year visual and anatomical outcomes after anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with photodynamic therapy (PDT), followed by pro re nata (PRN) anti-VEGF therapy with or without PDT, for polypoidal choroidal vasculopathy (PCV). The study sample consisted of 61 consecutive individuals with treatment-naïve symptomatic PCV who were followed for 5 years. The investigators found that a PRN regimen for PCV may have a limited impact for the long-term maintenance of improved VA. Data suggested that macular atrophy might occur more frequently with combination therapy and may be possibly related to 5-year VA. For patients susceptible to macular atrophy, the authors suggested that combination therapy should be deliberately chosen.